MK0859 Dose-Ranging Study (0859-003)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 2

Conditions: Mixed Hyperlipemia; Hypercholesterolemia

Treatments: Drug: MK0859

Study type: Interventional

Funder types: Industry

Identifiers

NCT00325455

2006_006

0859-003

Details and patient eligibility

About

To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.

Enrollment: 500 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eligible patients will be men and women of non-child bearing potential, 18 through 75 years of age diagnosed with high cholesterol

Exclusion criteria

• Patients with CHD or CHD-equivalent disease (except diabetes)
• Diabetics on statins

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind